JP2021054859A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021054859A5 JP2021054859A5 JP2021000870A JP2021000870A JP2021054859A5 JP 2021054859 A5 JP2021054859 A5 JP 2021054859A5 JP 2021000870 A JP2021000870 A JP 2021000870A JP 2021000870 A JP2021000870 A JP 2021000870A JP 2021054859 A5 JP2021054859 A5 JP 2021054859A5
- Authority
- JP
- Japan
- Prior art keywords
- fragment
- binding protein
- derived
- cell
- fully human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000024070 binding proteins Human genes 0.000 claims 10
- 108091007650 binding proteins Proteins 0.000 claims 10
- 102000004965 antibodies Human genes 0.000 claims 4
- 108090001123 antibodies Proteins 0.000 claims 4
- 102100013078 CD47 Human genes 0.000 claims 3
- 101700033237 CD47 Proteins 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 210000003719 B-Lymphocytes Anatomy 0.000 claims 2
- 230000035693 Fab Effects 0.000 claims 2
- 206010024324 Leukaemias Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010025310 Other lymphomas Diseases 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010024305 Leukaemia monocytic Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 210000000138 Mast Cells Anatomy 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 210000001744 T-Lymphocytes Anatomy 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000038129 antigens Human genes 0.000 claims 1
- 108091007172 antigens Proteins 0.000 claims 1
- 210000004027 cells Anatomy 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 201000006894 monocytic leukemia Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 210000003757 neuroblast Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Claims (8)
- ＣＤ４７に結合することができる結合タンパク質またはその抗原結合断片であって、
該結合タンパク質または断片は、ＣＤ４７エピトープに結合するＩｇＧクラスの単離された完全ヒト抗ＣＤ４７抗体、および、その抗ＣＤ４７完全ヒト抗体Ｆａｂ断片からなる群より選択され；
該結合タンパク質または断片は、配列番号２２のアミノ酸配列を含む重鎖可変ドメインと、配列番号８のアミノ酸配列を含む軽鎖可変ドメインとを含む、
結合タンパク質または断片。 - 前記ＩｇＧクラスの単離された完全ヒト抗ＣＤ４７抗体である、請求項１に記載の結合タンパク質または断片。
- 前記抗ＣＤ４７完全ヒト抗体Ｆａｂ断片である、請求項１に記載の結合タンパク質または断片。
- １×１０ −６ Ｍ以下のＫ Ｄ でＣＤ４７エピトープに結合する、請求項１〜３のいずれか一項に記載の結合タンパク質または断片。
- 請求項１〜４のいずれか一項に記載の結合タンパク質または断片を含む、がんの治療に使用するための組成物。
- 前記がんが、卵巣がん、結腸がん、乳がん、肺がん、骨髄腫、神経芽球由来のＣＮＳ腫瘍、単球性白血病、Ｂ細胞由来の白血病、Ｔ細胞由来の白血病、Ｂ細胞由来のリンパ腫、Ｔ細胞由来のリンパ腫、および肥満細胞由来の腫瘍からなる群より選択される、請求項５に記載の組成物。
- 請求項１〜４のいずれか一項に記載の結合タンパク質または断片と、医薬として許容される担体とを含む医薬組成物。
- 請求項１〜４のいずれか一項に記載の結合タンパク質または断片を含む、医薬として使用するための組成物。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021089081A JP2021121635A (ja) | 2015-03-04 | 2021-05-27 | Ｃｄ４７に結合する抗体医薬 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562128462P | 2015-03-04 | 2015-03-04 | |
| US62/128,462 | 2015-03-04 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019186564A Division JP2020023532A (ja) | 2015-03-04 | 2019-10-10 | Ｃｄ４７に結合する抗体医薬 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021089081A Division JP2021121635A (ja) | 2015-03-04 | 2021-05-27 | Ｃｄ４７に結合する抗体医薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021054859A JP2021054859A (ja) | 2021-04-08 |
| JP2021054859A5 true JP2021054859A5 (ja) | 2021-07-26 |
| JP7137646B2 JP7137646B2 (ja) | 2022-09-14 |
Family
ID=56848772
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017546200A Active JP6643350B2 (ja) | 2015-03-04 | 2016-03-04 | Ｃｄ４７に結合する抗体医薬 |
| JP2019186564A Withdrawn JP2020023532A (ja) | 2015-03-04 | 2019-10-10 | Ｃｄ４７に結合する抗体医薬 |
| JP2021000869A Active JP7105938B2 (ja) | 2015-03-04 | 2021-01-06 | Ｃｄ４７に結合する抗体医薬 |
| JP2021000870A Active JP7137646B2 (ja) | 2015-03-04 | 2021-01-06 | Ｃｄ４７に結合する抗体医薬 |
| JP2021089081A Withdrawn JP2021121635A (ja) | 2015-03-04 | 2021-05-27 | Ｃｄ４７に結合する抗体医薬 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017546200A Active JP6643350B2 (ja) | 2015-03-04 | 2016-03-04 | Ｃｄ４７に結合する抗体医薬 |
| JP2019186564A Withdrawn JP2020023532A (ja) | 2015-03-04 | 2019-10-10 | Ｃｄ４７に結合する抗体医薬 |
| JP2021000869A Active JP7105938B2 (ja) | 2015-03-04 | 2021-01-06 | Ｃｄ４７に結合する抗体医薬 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021089081A Withdrawn JP2021121635A (ja) | 2015-03-04 | 2021-05-27 | Ｃｄ４７に結合する抗体医薬 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10035855B2 (ja) |
| EP (1) | EP3265125A4 (ja) |
| JP (5) | JP6643350B2 (ja) |
| KR (2) | KR20240007967A (ja) |
| CN (2) | CN107921121B (ja) |
| AR (1) | AR103868A1 (ja) |
| AU (2) | AU2016225993B2 (ja) |
| CA (1) | CA2978594A1 (ja) |
| IL (2) | IL254321B (ja) |
| MX (1) | MX2017011329A (ja) |
| TW (2) | TWI778518B (ja) |
| WO (1) | WO2016141328A2 (ja) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3538557A4 (en) * | 2016-11-08 | 2020-11-18 | Ablexis, LLC | ANTI-CD47 ANTIBODIES |
| AU2018213718B2 (en) * | 2017-01-26 | 2022-08-25 | Zlip Holding Limited | CD47 antigen binding unit and uses thereof |
| EP3589368A4 (en) * | 2017-02-28 | 2021-03-24 | The Board of Trustees of the Leland Stanford Junior University | ANTIFIBROTIC EFFECTS OF THE CD47 BLOCKADE |
| BR112020001679A2 (pt) | 2017-08-02 | 2020-07-21 | Phanes Therapeutics, Inc. | anticorpos anti-cd47 e usos dos mesmos |
| US20200354458A1 (en) * | 2017-11-20 | 2020-11-12 | Taizhou Mabtech Pharmaceutical Co., Ltd. | Bifunctional Fusion Protein Targeting CD47 and PD-L1 |
| EA202091339A1 (ru) | 2017-12-01 | 2020-10-21 | Сиэтл Дженетикс, Инк. | Антитела против cd47 и их применение для лечения онкологических заболеваний |
| CN110577597B (zh) * | 2018-06-11 | 2021-10-22 | 康诺亚生物医药科技（成都）有限公司 | 一种阻断CD47和SIRPα相互作用的抗体 |
| CN112601544A (zh) * | 2018-07-05 | 2021-04-02 | 三钰生物科技股份有限公司 | 人类抗cd47抗体及其用途 |
| WO2020088580A1 (en) * | 2018-10-31 | 2020-05-07 | I-Mab Biopharma Co., Ltd. | Novel cd47 antibodies and methods of using same |
| CA3145791A1 (en) | 2019-07-16 | 2021-01-21 | Gilead Sciences, Inc. | Hiv vaccines and methods of making and using |
| US11795223B2 (en) | 2019-10-18 | 2023-10-24 | Forty Seven, Inc. | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
| AU2020374947A1 (en) | 2019-10-31 | 2022-03-31 | Forty Seven, Inc. | Anti-CD47 and anti-CD20 based treatment of blood cancer |
| TW202134280A (zh) * | 2019-12-05 | 2021-09-16 | 美商索倫多醫療公司 | 包含抗cd47抗體與腫瘤靶向抗體之組合物及方法 |
| GB201918230D0 (en) | 2019-12-11 | 2020-01-22 | Prec Therapeutics Ltd | Antibodies and their uses |
| CN113004406B (zh) * | 2019-12-20 | 2022-04-26 | 广东菲鹏制药股份有限公司 | 抗cd47抗体及其应用 |
| MX2022007930A (es) | 2019-12-24 | 2022-08-08 | Carna Biosciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| PE20231067A1 (es) | 2020-02-14 | 2023-07-17 | Jounce Therapeutics Inc | Anticuerpos y proteinas de fusion que se unen a ccr8 y usos de estos |
| WO2022109227A1 (en) * | 2020-11-19 | 2022-05-27 | Icahn School Of Medicine At Mount Sinai | Combined cancer therapy of b7-h3 and cd47 immune checkpoint inhbitior and methods of use |
| WO2022148383A1 (en) * | 2021-01-05 | 2022-07-14 | National Institute Of Biological Sciences, Beijing | A bispecific antibody targeting gpc3 and cd47 |
| EP4304633A1 (en) | 2021-03-12 | 2024-01-17 | Mendus B.V. | Methods of vaccination and use of cd47 blockade |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| WO2022235127A1 (ko) | 2021-05-07 | 2022-11-10 | 주식회사 이뮨온시아 | Cd47 및 pd-l1에 특이적으로 결합하는 이중특이적 항체 |
| KR20240023628A (ko) | 2021-06-23 | 2024-02-22 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| US11926628B2 (en) | 2021-06-23 | 2024-03-12 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| IL309378A (en) | 2021-06-23 | 2024-02-01 | Gilead Sciences Inc | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS |
| WO2022271684A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CN118139858A (zh) | 2021-10-28 | 2024-06-04 | 吉利德科学公司 | 吡地嗪-3(2h)-酮衍生物 |
| AU2022376954A1 (en) | 2021-10-29 | 2024-05-02 | Gilead Sciences, Inc. | Cd73 compounds |
| KR102438419B1 (ko) * | 2021-12-01 | 2022-09-01 | 메디포스트(주) | Cd47 과발현 중간엽 줄기세포를 포함하는 폐 질환 예방 또는 치료용 조성물 |
| WO2023122615A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| AU2022419982A1 (en) | 2021-12-22 | 2024-06-06 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| TW202346277A (zh) | 2022-03-17 | 2023-12-01 | 美商基利科學股份有限公司 | Ｉｋａｒｏｓ鋅指家族降解劑及其用途 |
| WO2023183817A1 (en) | 2022-03-24 | 2023-09-28 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| TW202345901A (zh) | 2022-04-05 | 2023-12-01 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| US20230374036A1 (en) | 2022-04-21 | 2023-11-23 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2024006929A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Cd73 compounds |
| WO2024015741A1 (en) | 2022-07-12 | 2024-01-18 | Gilead Sciences, Inc. | Hiv immunogenic polypeptides and vaccines and uses thereof |
| WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7138496B2 (en) * | 2002-02-08 | 2006-11-21 | Genetastix Corporation | Human monoclonal antibodies against human CXCR4 |
| EP2111869A1 (en) * | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
| EP2569013B1 (en) * | 2010-05-14 | 2016-11-23 | The Board of Trustees of the Leland Stanford Junior University | Humanized and chimeric monoclonal antibodies to cd47 |
| US9045541B2 (en) * | 2012-02-06 | 2015-06-02 | Inhibrx Llc | CD47 antibodies and methods of use thereof |
| NZ630563A (en) * | 2012-09-27 | 2017-04-28 | Merus Nv | Bispecific igg antibodies as t cell engagers |
| ES2784631T3 (es) * | 2012-12-03 | 2020-09-29 | Novimmune Sa | Anticuerpos anti-CD47 y métodos de uso de los mismos |
| JP6572131B2 (ja) * | 2012-12-12 | 2019-09-04 | バスキュロックス インコーポレイテッド | 治療用ｃｄ４７抗体 |
| KR102170196B1 (ko) * | 2013-02-06 | 2020-10-26 | 인히브릭스, 인크. | 비-혈소판 및 비-적혈구 세포 격감성 cd47 항체 및 이를 이용하는 방법 |
-
2016
- 2016-03-04 EP EP16759606.3A patent/EP3265125A4/en active Pending
- 2016-03-04 KR KR1020247000720A patent/KR20240007967A/ko active Application Filing
- 2016-03-04 TW TW110105132A patent/TWI778518B/zh active
- 2016-03-04 CN CN201680024600.9A patent/CN107921121B/zh active Active
- 2016-03-04 TW TW105106782A patent/TWI719966B/zh active
- 2016-03-04 JP JP2017546200A patent/JP6643350B2/ja active Active
- 2016-03-04 AR ARP160100592A patent/AR103868A1/es unknown
- 2016-03-04 CA CA2978594A patent/CA2978594A1/en active Pending
- 2016-03-04 US US15/061,771 patent/US10035855B2/en active Active
- 2016-03-04 MX MX2017011329A patent/MX2017011329A/es unknown
- 2016-03-04 CN CN202210050901.6A patent/CN114380912A/zh active Pending
- 2016-03-04 WO PCT/US2016/020980 patent/WO2016141328A2/en active Application Filing
- 2016-03-04 KR KR1020177028115A patent/KR102625835B1/ko active IP Right Grant
- 2016-03-04 AU AU2016225993A patent/AU2016225993B2/en active Active
-
2017
- 2017-09-04 IL IL254321A patent/IL254321B/en unknown
-
2019
- 2019-10-10 JP JP2019186564A patent/JP2020023532A/ja not_active Withdrawn
-
2020
- 2020-12-21 AU AU2020294159A patent/AU2020294159B2/en active Active
-
2021
- 2021-01-06 JP JP2021000869A patent/JP7105938B2/ja active Active
- 2021-01-06 JP JP2021000870A patent/JP7137646B2/ja active Active
- 2021-05-27 JP JP2021089081A patent/JP2021121635A/ja not_active Withdrawn
- 2021-11-09 IL IL287958A patent/IL287958A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021054859A5 (ja) | ||
| JP2018510147A5 (ja) | ||
| JP2018510151A5 (ja) | ||
| JP2019214586A5 (ja) | ||
| JP2018510865A5 (ja) | ||
| JP2017048240A5 (ja) | ||
| JP2016537383A5 (ja) | ||
| HRP20231281T1 (hr) | Bispecifična anti-muc16-cd3 antitijela i konjugati anti-muc16 s lijekom | |
| WO2016191246A3 (en) | T cell receptor-like antibodies specific for a prame peptide | |
| JP2018504105A5 (ja) | ||
| JP2017504578A5 (ja) | ||
| JP2021102633A5 (ja) | ||
| JP2017176174A5 (ja) | ||
| JP2016521692A5 (ja) | ||
| JP2018536393A5 (ja) | ||
| ES2572231T3 (es) | Anticuerpos monoclonales anti-IL-21 humana | |
| RU2016150377A (ru) | Сайт-специфичная конъюгация линкерных лекарственных препаратов с антителами и получаемые в результате adc | |
| JP2013506428A5 (ja) | ||
| JP2014518615A5 (ja) | ||
| JP2011505146A5 (ja) | ||
| NZ621938A (en) | Folate receptor 1 antibodies and immunoconjugates and uses thereof | |
| PE20220142A1 (es) | Anticuerpos de cadena pesada que se unen al psma | |
| JP2012503203A5 (ja) | ||
| DE602006013029D1 (de) | Anti-egfr-antikörper | |
| JP2009225799A5 (ja) |